IP Library Granted Patent US 12,409,270
Granted Patent B2
US 12,409,270 · App. 17/752,236 · Granted Sep 9, 2025

Optimizing embedded formulations for drug delivery

Inventors: Joon Bok Lee (Acton, MA); Yibin Zheng (Hartland, WI); Jason O'Connor (Acton, MA); Ashutosh Zade (San Diego, CA)
Assignee: INSULET CORPORATION
A61M5/1723A61M5/14244G16H20/17A61M2005/14208A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,409,270
App. No.
17/752,236
Granted
Sep 9, 2025
Kind
B2
Abstract

Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.

Claims (42)

1. A method comprising:

determining a search space of possible drug delivery amounts for a current cycle of medication delivery in an automated drug delivery system;

separating the search space into ranges of solutions;

narrowing the search space by determining a selected range in the range of solutions that minimizes a cost function;

separating the selected range into a list of refined values for a first delivery of the drug, the list of refined values being separated by a first fine increment;

evaluating a set of subsequent deliveries of the drug following the first deliveries of the drug in the list of refined values, the set of subsequent deliveries being separated by a second coarse increment; and

selecting a solution based on the set of subsequent deliveries that minimizes the cost function.

2. The method of claim 1 , wherein the first fine increment is smaller than the second coarse increment.

3. The method of claim 1 , wherein separating the search space into ranges of solutions is performed using a third coarse increment.

4. The method of claim 1 , wherein the search space of possible drug delivery amounts ranges from zero to a maximum quantity according to one or more safety constraints.

5. The method of claim 1 , wherein the drug is insulin and the automated drug delivery system is a part of a wearable drug delivery device.

6. The method of claim 1 , wherein determining the selected range comprises evaluating a recursive glucose model configured to predict glucose levels of a user of the automated drug delivery system in a predetermined number of future cycles based on delivery of a particular quantity of insulin.

7. The method of claim 6 , wherein the cost function calculates the cost for each possible glucose and insulin trajectory and determines the trajectory with a lowest cost.

8. A non-transitory computer-readable medium storing instructions configured to cause a processor to:

determine a search space of possible drug delivery amounts for a current cycle of medication delivery in an automated drug delivery system;

separate the search space into ranges of solutions;

narrow the search space by determining a selected range in the range of solutions that minimizes a cost function;

separate the selected range into a list of refined values for a first delivery of the drug, the list of refined values being separated by a first fine increment;

evaluate a set of subsequent deliveries of the drug following the first deliveries of the drug in the list of refined values, the set of subsequent deliveries being separated by a second coarse increment; and

select a solution based on the set of subsequent deliveries that minimizes the cost function.

9. The medium of claim 8 , wherein the first fine increment is smaller than the second coarse increment.

10. The medium of claim 8 , wherein separating the search space into ranges of solutions is performed using a third coarse increment.

11. The medium of claim 8 , wherein the search space of possible drug delivery amounts ranges from zero to a maximum quantity according to one or more safety constraints.

12. The medium of claim 8 , wherein the drug is insulin and the automated drug delivery system is a part of a wearable drug delivery device.

13. The medium of claim 8 , wherein determining the selected range comprises evaluating a recursive glucose model configured to predict glucose levels of a user of the automated drug delivery system in a predetermined number of future cycles based on delivery of a particular quantity of insulin.

14. The medium of claim 8 , wherein the cost function calculates the cost for each possible glucose and insulin trajectory and determines the trajectory with a lowest cost.

15. An automated drug delivery system comprising:

a reservoir configured to store a drug;

a drug delivery device configured to dispense the drug to a user;

a processor; and

a non-transitory computer-readable medium storing instructions configured to cause the processor to:

determine a search space of possible drug delivery amounts for a current cycle of medication delivery;

separate the search space into ranges of solutions;

narrow the search space by determining a selected range in the range of solutions that minimizes a cost function;

separate the selected range into a list of refined values for a first delivery of the drug, the list of refined values being separated by a first fine increment;

evaluate a set of subsequent deliveries of the drug following the first deliveries of the drug in the list of refined values, the set of subsequent deliveries being separated by a second coarse increment; and

select a solution based on the set of subsequent deliveries that minimizes the cost function.

16. The system of claim 15 , wherein the first fine increment is smaller than the second coarse increment.

17. The system of claim 15 , wherein separating the search space into ranges of solutions is performed using a third coarse increment.

18. The system of claim 15 , wherein the search space of possible drug delivery amounts ranges from zero to a maximum quantity according to one or more safety constraints.

19. The system of claim 15 , wherein the drug is insulin and the automated drug delivery system is a part of a wearable drug delivery device.

20. The system of claim 15 , wherein determining the selected range comprises evaluating a recursive glucose model configured to predict glucose levels of the user in a predetermined number of future cycles based on delivery of a particular quantity of insulin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2022
From: LEE, JOON BOK; ZHENG, YIBIN; O'CONNOR, JASON; ZADE, ASHUTOSH
To: INSULET CORPORATION
Reel/Frame 060000/0424 →
Continuity (2)
Continuation 17539270 · Dec 1, 2021
Related Publication 20230166034A1 · Jun 1, 2023
References Cited (48)
US 5007286A · Malcolm et al. · 1991 [cited by applicant]
US 6544212B2 · Galley · 2003 [cited by examiner]
US 6553841B1 · Blouch · 2003 [cited by applicant]
US 10332632B2 · Duke et al. · 2019 [cited by applicant]
US 10737024B2 · Schmid · 2020 [cited by applicant]
US 10881792B2 · Mazlish · 2021 [cited by examiner]
US 10987468B2 · Mazlish et al. · 2021 [cited by applicant]
US 20140146202A1 · Boss et al. · 2014 [cited by applicant]
US 20150120317A1 · Mayou et al. · 2015 [cited by applicant]
US 20150134265A1 · Kohlbrecher et al. · 2015 [cited by applicant]
US 20160038673A1 · Morales · 2016 [cited by applicant]
US 20160354543A1 · Cinar et al. · 2016 [cited by applicant]
US 20180200434A1 · Mazlish et al. · 2018 [cited by applicant]
US 20200342974A1 · Chen et al. · 2020 [cited by applicant]
US 20210098105A1 · Lee et al. · 2021 [cited by applicant]
US 20220023536A1 · Graham et al. · 2022 [cited by applicant]
AU 2015200834A1 · 2015 [cited by applicant]
EP 2897071B1 · 2019 [cited by applicant]
JP 2019525276A · 2019 [cited by applicant]
WO 2005082436A1 · 2005 [cited by applicant]
WO 2007078937A1 · 2007 [cited by applicant]
WO 2010053702A1 · 2010 [cited by applicant]
WO 2010132077A1 · 2010 [cited by applicant]
WO 2010138848A1 · 2010 [cited by applicant]
WO 2015187366A1 · 2015 [cited by applicant]
WO 2016004088A1 · 2016 [cited by applicant]
WO 2017091624A1 · 2017 [cited by applicant]
WO 2019213493A1 · 2019 [cited by applicant]
WO 2021011738A1 · 2021 [cited by applicant]
WO 2021026004A1 · 2021 [cited by applicant]
WO 2021163326A1 · 2021 [cited by applicant]
Fox, Ian G.; Machine Learning for Physiological Time Series: Representing and Controlling Blood Glucose for Diabetes Management; University of Michigan. ProQuest Dissertations Publishing, 2020. 28240142. (Year: 2020). [cited by applicant]
Villareal et al. (2009) in: Distr. Comp. Art. Intell. Bioninf. Soft Comp. Amb. Ass. Living; Int. Work Conf. Art. Neural Networks (IWANN) 2009, Lect. Notes Comp. Sci. vol. 5518; S. Omatu et al. (Eds.), pp. 870-877. [cited by applicant]
Medication Bar Code System Implementation Planning Section II: Building the Case for Automated Identification of Medications, Aug. 2013. [cited by applicant]
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/019079, mailed Jun. 2, 2022, 14 pages. [cited by applicant]
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/018453, mailed Jun. 2, 2022, 13 pages. [cited by applicant]
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/018700, mailed Jun. 7, 2022, 13 pages. [cited by applicant]
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/019080, mailed Jun. 7, 2022, 14 pages. [cited by applicant]
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/019664, mailed Jun. 7, 2022, 14 pages. [cited by applicant]
International Search Report and Written Opinion for the International Patent Application No. PCT/US21/060618, mailed Mar. 21, 2022, 15 pages. [cited by applicant]
Herrero Pau et al: “Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal bolus calculator—in silicoevaluation under intra-day variability”, Computer Methods and Programs in Biomedicin… [cited by applicant]
Marie Aude Qemerais: “Preliminary Evaluation of a New Semi-Closed-Loop Insulin Therapy System over the prandial period in Adult Patients with type I diabetes: the WP6. 0 Diabeloop Study”, Journal of Diabetes Science and… [cited by applicant]
Anonymous: “Kernel density estimation”, Wikipedia, Nov. 13, 2020 (Nov. 13, 2020), pp. 1-12, XP055895569, Retrieved from the Internet: URL:https://en.wikipedia.org/w/index.php? title=Kernel_density_estimation&oldid=98850… [cited by applicant]
Anonymous: “openaps / oref0 /lib/determine-basal-js”, openaps repository, Nov. 9, 2019 (Nov. 9, 2019), pp. 1-17, XP055900283, Retrieved from the Internet: URL:https://github.com/openaps/oref0/blob/master/lib/determine-b… [cited by applicant]
Anonymous: “AndroidAPS screens”, AndroidAPS documentation, Oct. 4, 2020 (Oct. 4, 2020), pp. 1-12, KP055894824, Retrieved from the Internet: URL:https://github.com/openaps/AndroidAPSdocs/blob/25d8acf8b28262b411b34f416f17… [cited by applicant]
Kozak Milos et al: “Issue #2473 of AndroidAPS”, MilosKozak / AndroidAPS Public repository, Mar. 4, 2020 (Mar. 4, 2020), pp. 1-4, XP055900328, Retrieved from the Internet: URL:https://github.com/MilosKozak/AndroidAPS/iss… [cited by applicant]
Medication Bar Code System Implementation Planning Section I: A Bar Code Primer for Leaders, Aug. 2013. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2022/051534, mailed Apr. 4, 2023, 10 pages. [cited by applicant]
Cited By (1)
US 12,661,488